Evidence map›Paper›PMID 38939727›Full record

ReviewClinical & translational immunology2024

Advances in bacteria-based drug delivery systems for anti-tumor therapy.

Han Shuwen, Song Yifei, Wu Xinyue, Qu Zhanbo, Yu Xiang, Yang Xi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical & translational immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Han ShuwenHuzhou Central Hospital Affiliated Central Hospital Huzhou Universityy Huzhou Zhejiang Province China.ORCID https://orcid.org/0000-0001-6180-9565
Song YifeiHuzhou Central Hospital Affiliated Central Hospital Huzhou Universityy Huzhou Zhejiang Province China.
Wu XinyueHuzhou Central Hospital Affiliated Central Hospital Huzhou Universityy Huzhou Zhejiang Province China.
Qu ZhanboHuzhou Central Hospital Affiliated Central Hospital Huzhou Universityy Huzhou Zhejiang Province China.
Yu XiangHuzhou Central Hospital Affiliated Central Hospital Huzhou Universityy Huzhou Zhejiang Province China.
Yang XiHuzhou Central Hospital Affiliated Central Hospital Huzhou Universityy Huzhou Zhejiang Province China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, bacteria have gained considerable attention as a promising drug carrier that is critical in improving the effectiveness and reducing the side effects of anti-tumor drugs. Drug carriers can be utilised in various forms, including magnetotactic bacteria, bacterial biohybrids, minicells, bacterial ghosts and bacterial spores. Additionally, functionalised and engineered bacteria obtained through gene engineering and surface modification could provide enhanced capabilities for drug delivery. This review summarises the current studies on bacteria-based drug delivery systems for anti-tumor therapy and discusses the prospects and challenges of bacteria as drug carriers. Furthermore, our findings aim to provide new directions and guidance for the research on bacteria-based drug systems.

Indexed as

anti‐tumorbacteriadrug delivery systemsynthetic biology

Identifiers

PMID38939727
PMCPMC11208082

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.